Jade Biosciences is dedicated to developing innovative therapies that address critical unmet needs in autoimmune diseases. The company is focused on its lead candidate, JADE101, which aims to inhibit the cytokine APRIL for the treatment of immunoglobulin A nephropathy (IgAN), a chronic kidney disease. JADE101 is designed to reduce harmful IgA antibodies, lower proteinuria, and preserve long-term kidney function, with ongoing clinical studies expected to yield interim data in 2026. Additionally, Jade's pipeline includes a second candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both in preclinical development. The company emphasizes a commitment to quality and compliance in its operations.